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Abstract
Results from different studies showing CB2 receptor-associated cardioprotective action
are  still  fairly  controversial  and no single  specific  mechanism could be identified.
Several groups investigated the involvement of the endocannabinoid system in cellular
systems and function of cardiomyocytes, fibroblasts, macrophages and endothelial cells.
While some studies are limited in their translational relevance, a few recent studies
describe a myocardial ischemia and reperfusion scenario in a fashion comparable to the
clinical  situation.  Recent  studies  provided  evidence  for  involvement  of  the  CB2
receptor–endocannabinoid axis in prevention of cardiomyocyte apoptosis including
modulation of antioxidative enzymes and contractile elements expression. CB2 receptor
has  further  been  shown  to  specifically  modulate  the  inflammatory  response  and
macrophage function after myocardial ischemia. These effects have an impact on the
subsequent myocardial remodeling, where the CB2 receptor modulates function of
myofibroblasts, collagen production and limitation of myocardial infarction size. Recent
experimental and clinical data showed the association of the endocannabinoid system
in myocardial hypertrophy. In conclusion, increasing amount of evidence supports a
crucial  role  of  the  endocannabinoid  system  in  cardioprotection  and  myocardial
remodeling, while some of them even suggest model-independent systemic effects in
adaptation of cardiomyocytes or components of the extracellular matrix.
Keywords: endocannabinoids, myocardial ischemia, reperfusion, cardioprotection, re‐
modeling
1. Introduction
Cannabinoids have been described as potent regulators of a variety of neurological functions
influencing pain control, behaviour and memory. The discovery of the cannabinoid receptors
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CB1 and CB2 led to initial description of CB1 receptor to be restricted to neurons while CB2
receptor was found on immunological cells. Later studies reported these receptors being also
localized on vascular cells [1] and in the heart [2]. Furthermore, production of ligands to the
cannabinoid receptors—endogenous cannabinoids—was reported in  endothelial  cells  [3].
Experiments performed in vitro and in vivo showed that the effects of endocannabinoids on the
cardiovascular  system are pleiotropic  and only partially understood to date.  Due to the
socioeconomic impact of cardiovascular diseases, a better understanding of the pathology and
associated mechanisms is needed for development of novel therapeutic strategies. Since modern
therapies are aiming to disease prevention with early treatment, the mechanisms of cardiopro‐
tection gained a significant attention and have been investigated more deeply. The cardiopro‐
tective mechanisms provide limitation of the myocardial damage after injury and are very
complex. Growing evidence supporting the role of inflammation in cardioprotection [4] and
modulation  of  inflammatory  response  by  endocannabinoids  led  to  investigations  of  the
endocannabinoids in myocardial injury and protection.
2. Mechanisms of cardioprotection
Myocardial protection is a very complex system involving not only intracellular mecha‐
nisms in cardiomyocytes, but also bearing a large contribution of cells within the local
microenvironment in the heart. The contradictions in the experimental evidence for specific
mechanisms in the cardiomyocytes are not only related to differences in experimental setup,
but also most probably associated to variations in mediators and cells within the local
microenvironment. These factors make it difficult to draw clear conclusions from experimen‐
tal data which will lead to new targets for therapy. Therefore, significant efforts have been
made to enlighten the complexity of cardioprotection.
A number of signalling cascades and systems are involved in cardioprotection. Based on strong
experimental and clinical evidence, the first line of intervention is aiming at the earliest possible
restoration of the blood flow, i.e., reperfusion. The very early observation of timely onset of
reperfusion leading to preservation of myocardial function [5, 6] provided ground for the
clinical introduction of early percutaneous coronary intervention. Subsequently, Murry
introduced the concept of ischemic preconditioning based upon four episodes of five mi‐
nutes ischemia interrupted by each five minutes of reperfusion before a myocardial infarc‐
tion was induced (40 minutes ischemia) and thereby resulting in decreased infarct size [7].
Interestingly, this effect was not found after a three-hour ischemia period underlining the
ultimate goal of early reperfusion. This concept of myocardial conditioning was first applied
in temporal relation to the myocardial injury, thereby defining preconditioning and postcon‐
ditioning [8]. Studies extended this concept by introduction of spatial component in remote
preconditioning, where short, repetitive limb occlusions provide protection to the following
longer episode of myocardial ischemia [9, 10]. The latter concept was clinically implemented
and proved to be beneficial to the patients [11]. Numerous studies described a wide range of
molecules and signalling cascades involved utilizing different models, species, and pharma‐
cological or genetic manipulation. So far there are only scattered reports investigating the role
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of endocannabinoids in ischemic preconditioning. One of the studies applied heat stress
preconditioning 24 hours before isolation of the hearts, which then underwent 30 min ischemia
and 120 minutes reperfusion ex vivo using Langendorff system [12]. The application of selective
CB2 receptor antagonist SR144528 reduced the protective effects of heart preconditioning on
infarct size. The authors therefore suggested a potential protective role of CB2 receptor in
ischemia and reperfusion (I/R).
Figure 1. Cascade of events after reperfusion of ischemic myocardium. I/R, ischemia and reperfusion; LAD, left anteri‐
or descending artery; LV, left ventricular.
Another important area of cardioprotection originated in studies describing effects of
modulation of inflammatory response during reperfusion injury. The very early studies
reported detrimental outcome in patients treated with methylprednisolone after reperfusion
of myocardial infarction [13]. Despite this drawback, it was the experimental work in subse‐
quent years which provided solid evidence for beneficial effects of reperfusion [14]. The effects
of inflammation in reperfusion must also be differentiated in a temporal and spatial context,
because reperfusion initially induces a strong inflammatory response. In short-term (few
days), this leads to a stronger functional impairment of the heart than without reperfusion,
but the long-term effects of reperfusion have been proven to preserve the myocardial function
and could even prevent development of dysfunction. The ischemia of myocardial tissue leads
to accumulation of free radicals and toxic metabolic products while the adenosine triphos‐
phate storages are depleted and cellular homeostasis is increasingly impaired. The reperfu‐
sion of ischemic myocardium is associated with activation of the complement system and a
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strong increase in reactive oxygen species (ROS). The subsequent response includes activa‐
tion of tumour necrosis factor α (TNF-α) and initiation of a cytokine response [15] leading to
a cascade of events (Figure 1). Activation of TNF-α leads to induction of interleukin (IL-)8 and
CC chemokine ligand (CCL)2, which – in combination with complement factor C5a activation
—attracts neutrophil granulocytes to the ischemic myocardium [16]. The extravasation of
neutrophils and the expression of intercellular adhesion molecule (ICAM-)1 lead to direct
adhesion of neutrophils on cardiomyocytes with damaging effects involving ROS [17]. The
ROS cause an oxidative burst leading to irreversible cellular damage [18] and is counteract‐
ed by different scavenger enzymes, e.g., peroxidases, superoxide dismutases (SODs) or
catalase. The damaged cardiomyocytes release chemokine CCL2 and cytokine transforming
growth factor (TGF-)β and thereby promote invasion of mononuclear cells [19].
Differentiation of monocytes to macrophages in myocardium leads to even further increased
production of inflammatory cytokines, while macrophages initiate their production of growth
factors, e.g., basic fibroblast growth factor or vascular endothelial growth factor. As a result,
proliferation of fibroblasts, differentiation of myofibroblasts and neoangiogenesis are initiated
and all aiming at granulation tissue formation and tissue remodeling. These events involve
different macrophage subpopulations, which are differentiated upon polarization of the
lymphocytes response from Th1 to Th2 type [20]. While previous studies described classical
proinflammatory M1 and alternative anti-inflammatory M2 subtype of macrophages, novel
studies provide evidence of even more subtypes of these crucial cells in tissue repair. The
application of so called cardiosphere-derived cells led to differentiation of a unique cardio‐
protective subtype of macrophages in infarcted rat hearts not bearing M1 or M2 markers and
resulting in reduction of infarct size [21]. The inflammatory response has to be deactivated at
the certain point of granulation tissue formation in order to provide rapid tissue remodeling
and formation of a stable scar. This resolution of inflammatory response is mediated by anti-
inflammatory cytokines, e.g., IL-10, which also inhibit matrix metalloproteinases (MMP) and
stimulate their counter actors, tissue inhibitors of MMP (TIMP) [22]. Therefore, the regula‐
tion of macrophage function during myocardial remodeling gained a strong attention in recent
years.
Among other factors, specific chemokines have been associated with modulation of macro‐
phage function. Chemokines are a subgroup of cytokines having distinct effects on mononu‐
clear cells and macrophages, but also on neutrophils and endothelial cells. One of the most
potent monocyte chemoattractants is the chemokine CCL2, which is associated with transen‐
dothelial migration and differentiation of monocytes into macrophages [23–25]. CCL2 is
induced by proinflammatory cytokines TNF-α and IL-1β [24] and mediates mononuclear cell
migration into reperfused myocardial infarction [26]. It has also been associated with differ‐
entiation of myofibroblasts and collagen production. Reperfusion of myocardial infarction in
CCL-deficient (CCL2-/-) mice was associated with prolonged inflammatory response and
delayed formation of granulation tissue resulting in attenuated myocardial remodeling [27].
This was accompanied by decreased differentiation of myofibroblasts and significantly larger
left ventricular diameter when compared with wild-type (WT) mice. Another study provid‐
ed additional evidence for a crucial role of chemokine CCL2 in the ischemic heart. In a model
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of repetitive brief I/R there was a significant reduction in collagen deposition and fibrosis
associated with no ventricular dysfunction in CCL2-/- mice when compared to interstitial
fibrosis and moderate dysfunction in WT animals [28]. Therefore, modulation of macro‐
phage function via pharmacological manipulation of chemokine expression profile could be a
promising target in development of novel clinical strategies.
3. Experimental evidence for involvement of endocannabinoids in
cardioprotection
One of the first publications reported a CB1 receptor-mediated decrease in contractility of
human atrial muscle [2]. Cannabinoids also led to a reduction of left ventricular systolic
pressure [29]. There is a certain variability in results between in vivo and ex vivo effects of
cannabinoids reported in the myocardium [30], the vasculature [31], the peripheral [32] and
the central nervous system. The alterations in vascular tone were accompanied by changes in
myocardial contractility and chronotropy and were associated to both CB1 receptor as well as
vanilloid receptor [33]. In regard to pathophysiology, beneficial effects were reported for the
experimental treatment of atherosclerosis using Δ-9-tetrahydrocannabinol (THC) [34]. In
contrast, the results of endocannabinoid effects in the heart were heterogenous. One group
reported triggering of heart attacks after use of marijuana [35], while other groups described
protective effects in ischemic heart disease upon a decrease in mortality after experimental
myocardial infarction [36], or anandamide-induced reduction of infarction size [37]. Still, the
underlying mechanisms are not well understood and many investigations aim to shed more
light into this clinically important filed. Myocardial I/R is always associated with inflamma‐
tory response and it is therefore likely that the endocannabinoid system may act in this process
via the CB2 receptor as it modulates the function of macrophages [38]. A cardioprotective role
has been postulated upon induction of extracellular signal-regulated kinases (ERK)1/2 after 30
minutes of myocardial ischemia and 10 minutes reperfusion in mice [39]. Another study
provided in vitro evidence of CB2 receptor-related cardioprotection in vitro using hydrogen
peroxide treatment leading to increased apoptosis of cardiomyocytes and higher differentia‐
tion potential of myofibroblasts [40]. The same report described CB2 receptor-dependent down
regulation of caspase 3 after one hour ischemia and three days reperfusion, but provided
surprising results in WT mice with normal left ventricular function after four weeks of
reperfusion accompanied by infarct size of only 4% of left ventricular area. Other studies aimed
to provide more insights into CB2 receptor mediated mechanisms in cardioprotection.
Application of a non-specific (acting on CB1 and CB2 receptor) agonist WIN55212-2 was shown
to reduce infarct size in a mouse model of coronary occlusion without reperfusion, while it
decreased myeloperoxidase activity of neutrophils [41]. CB2 receptor can influence the Th1/
Th2-polarization of lymphocytes in vitro, which is an important step in differentiation of
macrophage subpopulations. This is relevant for cardiac repair since macrophage subpopu‐
lations are involved in granulation tissue formation [20], remodeling and scar formation via
modulation of fibroblasts and differentiation of myofibroblasts. The myofibroblasts are the
major source of extracelullar matrix components and thereby play a crucial role in tissue
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remodeling. In this context, CB2 receptor has been associated with regulation of myofibro‐
blast differentiation in a murine liver fibrosis model [42].
Recent work from our group investigated the role of endocannabinoids and CB2 receptor in a
mouse model of non-infarcted ischemic cardiomyopathy induced by brief repetitive I/R.
Repetitive daily episode of 15 minute ischemia followed by reperfusion until the next day lead
to a transient inflammatory reaction, development of interstitial fibrosis and left ventricular
dysfunction [43]. We could show that fibrosis and dysfunction are reversible after 60 days of
recovery after the last episode of I/R, where normal left ventricular myocardium is found. This
is of clinical interest since: (a) repetitive episodes of ischemia are the hallmark of angina pectoris
in patients and (b) these functional and morphological characteristics are also found in human
hibernating myocardium with restoration of normal function after revascularization [8]. Mice
with overexpression of SOD showed significantly less inflammation and fibrotic depositions
associated with almost normal left ventricular function in this model and thereby revealed the
importance of ROS in development of fibrosis and left ventricular dysfunction [43]. Another
study in the same mouse model revealed a crucial role for the chemokine CCL2 in develop‐
ment of interstitial fibrosis and left ventricular dysfunction [28]. It was therefore a logical next
step to utilize CB2-deficient (Cnr2-/-) mice in model of repetitive, brief I/R [44]. In an initial set
of experiments, we found persistent induction of CB2 receptor in WT hearts upon repetitive
I/R. Since there is no reliable CB2 antibody for histological detection in mice available we
isolated cardiomyocytes using Langendorff apparatus and after their purification we could
demonstrate induction of Cnr2 mRNA selectively in cardiomyocytes. Cnr2-/- mice underwent
the repetitive I/R protocol and presented with small infarcted areas—microinfarctions—
indicating irreversible loss of cardiomyocytes already after three days I/R. The discontinua‐
tion of the I/R protocol led to no restoration of the left ventricular function in Cnr2-/- mice after 60
days, in contrast to full recovery in WT mice. WT hearts showed a transient increase in
production of anandamide in parallel to the inflammatory reaction, whereas 2-arachidonoyl‐
glycerol (2-AG) level was elevated only after 7 days I/R. These data clearly showed not only
the involvement of CB2 receptor and endocannabinoids in ischemic myocardium, but also
provided a time course of their expression. The study revealed increased apoptosis and ROS
production in Cnr2-/- hearts when compared to the WT mice. The investigation of mecha‐
nisms associated to the increased apoptosis in Cnr2-/- hearts revealed a CB2 receptor-associat‐
ed regulation in expression of contractile elements and antioxidative enzymes (Figure 2).
Analysis of inflammatory response revealed a CB2 receptor dependent induction of the
cytokine IL-1β and the chemokines CCL2, CCL3 and CCL4 in this model. Interestingly, Cnr2-/-
mice were able to induce the inflammatory response by a stronger induction of monocyte-
colony stimulating factor (M-CSF) and TNF-α than the WT mice. This led to persistent
macrophage infiltration of the ischemic myocardium in Cnr2-/- mice, while they were also
unable to induce the anti-inflammatory cytokine IL-10 and thereby resolve the inflammatory
response. Magnetic sorting of macrophages using flow cytometry and their mRNA expres‐
sion profile provided evidence for a delayed initiation of the anti-inflammatory M2a subpo‐
pulation of macrophages in Cnr2-/- mice. Additional experiments using reconstituted chimeric
mice provided additional evidence for the pivotal role of macrophages in the irreversible loss
of cardiomyocytes in Cnr2-/- mice.
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Figure 2. CB2 receptor-dependent mechanisms of cardioprotection in ischemic non-infarcted murine myocardium. I/R,
ischemia and reperfusion; HMOX, heme oxygenase; GPX, glutathione peroxidase; MHC, myosin heavy chain; 2-AG, 2-
arachidonoylglycerol; TNF-α, tumour necrosis factor α.
The consequences of prolonged inflammatory response were not limited to cardiomyocyte
loss, but also involved adverse remodeling process in Cnr2-/- hearts. A morphological differ‐
entiation of collagen deposition revealed a comparable collagen area between the two
genotypes, but significantly less interstitial fibrosis and concentration of collagen in microin‐
farctions in Cnr2-/- hearts [44]. At the molecular level this was associated with significantly less
mRNA expression of collagen III, which is the reversible form of the deposited collagen
isoforms. The significantly lower differentiation of myofibroblasts was associated with a low
expression or early remodeling marker tenascin C in vivo and in vitro. Taken together, the
survival of non-infarcted ischemic myocardium is dependent on a complex involvement of
endocannabinoids and CB2 receptor in molecular and cellular mechanisms of cardioprotec‐
tion.
Based on these findings we utilized Cnr2-/- mice in a model of reperfused myocardial infarc‐
tion. One hour of ischemia was followed by reperfusion for different time periods up to seven
days and led to a significantly worse left ventricular function in Cnr2-/- mice when compared
to the WT mice [45]. Histological analysis showed expansion of the infarcted area as a
transmural lesion in Cnr2-/- when compared to the non-transmural scar formation in WT mice.
Myocardial infarction was associated with increased production of anandamide and 2-AG,
but also of their associated lipids oleoyl ethanolamine and palmitoyl ethanolamide in both
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genotypes. The molecular analysis showed a similar pattern as in non-infarcted repetitive I/R,
with an impaired induction of antioxidative enzymes and unfavourable expression of
contractile elements in Cnr2-/- mice. Molecular analysis revealed an IL-1β- and TNF-α-associ‐
ated induction of inflammatory response with only low-level chemokine response after six
hours of reperfusion in Cnr2-/- mice. In contrast WT mice showed a regular pattern with a
significant increase in expression of TNF-α and chemokines CCL2, CCL3 and CCL4. The
significantly higher density of macrophages was associated with their prolonged action in
infarction until seven days reperfusion and their completely transmural involvement in Cnr2-/-
mice [45]. The analysis of myocardial remodeling revealed significantly less myofibroblasts
and a lower induction of tenascin C in Cnr2-/- hearts. The most important finding was the lack
of thrombospondin 1 induction in Cnr2-/- hearts, which was responsible for the impaired
formation of the infarction border zone and thereby failed limitation of the myocardial injury.
In summary, our in vivo studies showed substantial involvement of endocannabinoids and
CB2 receptor in cardioprotective mechanisms and subsequent myocardial remodeling in the
murine heart. While their clinical relevance still remains to be investigated, it is even more
important to better understand the molecular mechanisms and the impact of cellular interac‐
tions mediated by this system.
4. Endocannabinoids in cellular mechanisms of myocardial adaptation
Several studies investigated the effects of cannabinoid receptors in regulation of cellular
homeostasis and pathology, but their methodological differences and model-related prob‐
lems do not allow to drawn clear and direct conclusions. A number of pharmacological studies
investigated the impact of cannabinoid receptors on blood pressure in vivo and ex vivo [46] and
some of these studies showed associated negative inotropic effects mediated by CB1 recep‐
tor. This was further supported by the evidence for CB1 receptor-mediated contractile
dysfunction in experimental models of hepatic cirrhosis [47]. Still, none of these studies
provided insights into specific cell actions of CB1 receptor. A study using 30 min left anteri‐
or descending artery (LAD) occlusion and 2.5 hours of reperfusion thereafter showed CB2
receptor effects by using non-specific agonist WIN55212-2 and reversal of its action with CB2
receptor antagonist AM630 [41]. Thereby, the authors described CB2 receptor-mediated effects
on inflammatory response and myeloperoxidase activity indicating general leukocyte
involvement. Another study utilized selective CB2 receptor agonist JWH-133 and showed
cardioprotective effects based on activation of ERK1/2 and the signal transducer and activa‐
tor of transcription (STAT)3-mediated pathway [39]. The same study described also attenuat‐
ed neutrophil recruitment towards inflammatory cytokine TNF-α in vitro.
Potential cardioprotective effects were described for cannabidiol based on the lower inci‐
dence of arrhythmia in rat hearts after ischemia and reperfusion, but the authors only
speculated about involvement of cardiac current and channels [48]. The already above
mentioned study suggested CB2 receptor-related cardioprotection after hydrogen peroxide
treatment leading to increased apoptosis of cardiomyocytes and higher differentiation
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potential of myofibroblasts in vitro [40]. Our own work provided evidence for increased mRNA
expression of Cnr2 in purified cardiomyocytes after three days of brief repetitive I/R [44].
Cardiomyocytes were isolated using enzyme digestion in Langendorff apparatus and
subsequent separation of them from fibroblasts was achieved using a short stay in cell culture
where fibroblasts attach rapidly to the dish. We also used embryonic cardiomyocyte cell
culture (having a large proportion of concomitant fibroblasts needed for survival) and were
able to show a lower induction of antioxidative enzyme heme oxygenase 1 and chemokine CCL2
in Cnr2-/- cells under hypoxic conditions (2% O2). In order to eliminate the confounding effects
of fibroblasts, we utilized puromycin-purified embryonic stem cell-derived cardiomyocytes
(97%-pure cardiomyocyte cell culture) [49]. This pure cardiomyocyte culture confirmed our
findings on heme oxygenase 1 and CCL2, and in addition provided evidence for hypoxia-
dependent up regulation of CB2 receptor [44]. These data clearly showed specific CB2 receptor-
related effects in cardiomyocytes.
Based on our data from cardiomyocytes in vitro and macrophage modulation in vivo we further
investigated cellular interactions between cardiomyocytes and macrophages [50]. Initially we
demonstrated the topical expression of CB2 receptor on WT cardiomyocytes and both WT
macrophage subtypes M1 and M2 in cell culture, which increased under hypoxic conditions
(2% O2) and even more when proinflammatory cytokine interferon (IFN)-γ was added into the
culture medium [50]. In order to exclude methodological problems of cell culture we quanti‐
fied the number of vital WT cardiomyocytes in the culture after 12 and 24 hours cultivation
under normoxia and hypoxia and found comparable cell numbers in both conditions, while
the number was slightly lower after 24 hours indicating only minor loss due to apoptosis. Next,
we compared apoptosis in WT vs. Cnr2-/- cardiomyocytes and found significantly higher
amount of apoptotic cells among the Cnr2-/- cardiomyocytes. This raised the question wheth‐
er the increased apoptosis alone is solely responsible for the loss of cardiomyocytes ob‐
served in our in vivo model, and we therefore investigated the function of macrophages in the
next step. We stimulated the macrophages with IFN-γ in order to stimulate the differentia‐
tion into M1 subtype [50]. In order to measure the migration potential of this subtype we used
either supernatant from the cardiomyocytes cell culture after 24 hours hypoxia or potent
chemoattractants CCL2 and M-CSF in a Boyden chamber, which are both strongly induced
after myocardial infarction in mice [51]. We found a significantly stronger migration poten‐
tial of Cnr2-/- M1 macrophages towards the supernatant of hypoxic cardiomyocytes than in WT
M1 macrophages. This finding indicated a more aggressive nature of Cnr2-/- M1 macrophag‐
es and we subsequently utilized them in co-culture with cardiomyocytes. The co-culture
experiments revealed significantly higher loss of embryonic cardiomyocytes and their
apoptosis when combined with Cnr2-/- than with WT M1 macrophages. In addition, we found
that production of TNF-α in M1 macrophages was dependent on stimulation of CB2 recep‐
tor by anandamide [50]. In summary, we were able to identify at least some of the mecha‐
nisms behind the aggressive nature of macrophages in Cnr2-/- mice and their interaction with
cardiomyocytes under conditions, which are comparable to the in vivo situation. Still, it remains
to be elucidated in future studies which molecular pathways are involved in this cellular
interaction and expand it towards other cells in the heart.
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5. Clinical perspective for endocannabinoids in myocardial adaptation
A number of clinical studies described the involvement of endocannabinoids in human cardiac
conditions. One study described an increased level of endocannabinoids in the blood stream
and higher expression of CB2 receptor in the heart of patients with terminal heart failure [52].
Another study from the same group described significant reduction of plasma anandamide
concentration after induction of general anaesthesia using isoflurane [53]. In the same patient
population they reported a significant increase in 2-AG after onset of cardiopulmonary bypass
during heart surgery, but remained only speculative on the clinical relevance of these findings
by suggesting association with inflammatory response. A recent study from our group showed
activation of the endocannabinoid system and up regulation of its receptors in myocardial
hypertrophy in patients with aortic valve stenosis [54]. We were able to identify expression of
CB2 receptor predominantly on cardiomyocytes, but also on myofibroblasts and mononu‐
clear cells in hypertrophic myocardium. The same study revealed a persistent low-grade
inflammation and active remodeling in hypertrophied hearts and this shows parallels to our
experimental findings discussed above.
Figure 3. Complex relations in a clinical scenario targeting endocannabinoid system.
The endocannabinoid system gained clinical relevance in the last few years because of a CB1-
receptor antagonist based therapy (rimonabant) being approved for clinical use in severely
obese patients, but then disappeared rather early due to unwanted and detrimental side
effects [55]. Still, one study investigated the effect of rimonabant on progression of atheroscle‐
rosis in patients with abdominal obesity and coronary artery disease (STRADIVARIUS
randomized controlled trial). The results were disappointing for the primary endpoint, since
no effect could be identified on the disease progression [56]. Still, the secondary endpoint of
normalized total atheroma volume was met and this could be the basis for future studies. In
the light of our results on the role of the chemokine CCL2 and the CB2 receptor in myocar‐
dial remodeling and adaptation to injury [27, 43–45], it has to be emphasised, that we need to
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expand our knowledge of cellular interactions and mechanisms in other disease models. The
complexity of this system and its interaction are shown in Figure 3. The next step will be the
investigation of highly specific compounds acting on cannabinoid receptors. Nevertheless, the
modulation of inflammatory response remains to be a potential therapeutical target in
cardioprotection.
6. Conclusions
Growing amount of evidence supports the role of the endocannabinoid system and cannabi‐
noid receptors in cardioprotection and myocardial adaptation. Several mechanisms have been
described in specific cells in vitro and some of these show parallels with the in vivo data. The
data on CB2 receptor-mediated adaptation of injured myocardium show a spatiotemporal
resolution of its actions on different cells in the heart and shed more light into the finely
balanced system of cardioprotection. Therefore, an even better mechanistic understanding of
the cannabinoid system and its action on the cardiovascular system in the healthy and the
diseased state are needed than the present one we have. This will eventually allow the
identification of promising new pathways and/or targets for the treatment of cardiovascular
diseases.
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